Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Status:
Not yet recruiting
Trial end date:
2028-02-29
Target enrollment:
Participant gender:
Summary
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis,
whether they can benefit from combination therapy has not been reported. This study aims to
investigate the efficacy and safety of combination therapy compared with furmonertinib
monotherapy in advanced EGFR mutant NSCLC with uncleared circulating tumor cell DNA.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Allist Pharmaceuticals, Inc. GeneCast Biotechnology Co., Ltd.